Fractyl Health to Participate in the Upcoming December Conferences
Rhea-AI Summary
Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company specializing in obesity and Type 2 Diabetes treatments, has announced its participation in two upcoming investor conferences. The company's Co-Founder and CEO, Harith Rajagopalan, M.D., Ph.D., will present at:
- The 7th Annual Evercore ISI HealthCONx Conference (Fireside Chat) on December 3, 2024, at 7:30 AM ET
- The Piper Sandler 36th Annual Healthcare Conference (Fireside Chat) on December 4, 2024, at 1:30 PM ET
Webcast replays will be available on the company's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – GUTS
In the trading session that priced this news, GUTS declined 4.41%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of the Company, will present at two upcoming investor conferences.
Details of the presentations can be found below.
7th Annual Evercore ISI HealthCONx Conference
Format: Fireside Chat
Date: 12/03/2024
Time: 7:30 AM ET
Piper Sandler 36th Annual Healthcare Conference
Format: Fireside Chat
Date: 12/04/2024
Time: 1:30 PM ET
Webcast replays will be accessible following the live sessions on the Events page of the Investors section on the Company’s website at https://ir.fractyl.com/.
About Fractyl Health
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit www.fractyl.com.
Contacts
Corporate Contact
Lisa Davidson, Chief Financial Officer
ir@fractyl.com, 781.902.8800
Media Contact
Jessica Cotrone, Corporate Communications
jcotrone@fractyl.com, 978.760.5622
Investor Contact
Stephen Jasper Gilmartin Group
stephen@gilmartinir.com, 619.949.3681
